Nature 444, 854859
A phase 2, randomized, dose-finding study of the novel once-weekly human glp-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes
The Ozempic vs Mounjaro comparison is therefore more accurately framed as: semaglutide (at diabetes doses, off-licence for weight loss) vs tirzepatide (licensed for weight management)
Its sad (r/PCOS, 533 upvotes)
The triple-receptor mechanism stood out because it targets appetite, insulin, and energy expenditure all at the same time, not just one pathway
To explore approved options available today, you can read about Voys licensed treatments or check your eligibility now.